Although there is MR evidence showing the potentially harmful effects of ACE inhibitors on colorectal cancer, of BBs on hepatocellular carcinoma, and of CCBs on prostate cancer, meta-analysis of RCTs consistently reported null [55, 64]. The gene discussed is ACE; the disease is hepatocellular carcinoma.